What is cytokine release syndrome?

Cytokine release syndrome is a reaction caused by a large, sudden release of cytokines into the blood. It is a known and serious side effect of CAR T-cell therapy. The National Cancer Institute explains that it happens "when the transferred T cells, or other immune cells responding to the new T cells, release a large amount of cytokines into the blood."

Cytokines are the immune system's messengers. NCI describes them as "chemical messengers that help stimulate and direct the immune response." Normally they are released in small, controlled amounts to call other immune cells to a problem.

Why the reaction happens

CAR T-cell therapy takes a patient's own T cells. A laboratory re-engineers them to recognize cancer cells. Then they go back in. When those cells find their target, they go to work at scale.

That is where the trouble starts. NCI puts it directly: "the infused T cells flood the bloodstream with cytokines... The overabundance of cytokines that happens with CRS, however, causes dangerously high fevers and precipitous drops in blood pressure."

So the syndrome is not an allergy and not an infection. It is the immune response itself, running far above its usual volume.

What it looks like

NCI lists the signs: fever, nausea, headache, rash, rapid heartbeat, low blood pressure, and trouble breathing.

Fever is usually first. These symptoms overlap with infection. So your team will often treat for both at once, until they know which one it is.

Severity varies a great deal. NCI says "most people have a mild form of cytokine release syndrome. But in some people, it may be severe or life-threatening." That range is why patients are monitored so closely in the days after an infusion.

It has a specific treatment

This matters, because it means the syndrome is not simply endured. NCI reports that "in many patients, both children and adults, CRS can be managed with tocilizumab (Actemra) and, if needed, steroids."

Tocilizumab is not a cancer drug at all. NCI notes it "was initially used to treat inflammatory conditions like juvenile arthritis" and that it "blocks the activity of IL-6, a cytokine that is often secreted in large amounts by immune cells." It targets one specific messenger rather than shutting down the immune system.

The other syndrome to know about

CAR T-cell therapy can also affect the brain. The condition is called ICANS. NCI says "some of the hallmark signs of ICANS include confusion, excessive sleepiness, and impaired speech," and that it "is also often treated with steroids."

That list is worth reading twice. A confused person cannot reliably report confusion. The people around the patient usually notice first.

What to do about it

CAR T-cell therapy is approved for several blood cancers. They include large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. If you or someone you care for is having it, ask the team two things before the infusion.

Ask which specific symptoms should trigger an immediate call, and what number to use at night. Then make sure the person staying with you knows both. Handwriting, word-finding, and unusual sleepiness are worth watching for as carefully as temperature.